Moore is Less
By Osagie K. Obasogie and Helen Theung,
Stanford Technology Law Review
| 01. 15. 2013
Why the Development of Pluripotent Stem Cells Might Lead Us to Rethink Differential Property Interests in Excised Human Cells
Since Moore v. Regents of the University of California, there has been a wide-ranging debate regarding the holding of the case and its implications for property law. Moore stands for the notion that individuals do not have a property interest in ordinary cells taken from their bodies during medical procedures nor the commercial products that researchers might develop from them. At the same time, cases such as Davis v. Davis and Hecht v. Superior Court have asserted that individuals maintain a property interest in other types of cells—namely embryos and gametes (eggs and sperm)—once they are removed from the body. This, among other developments, has led to a fragmented regime in property law pertaining to excised biological materials that turns, in large part, on the type of cell in question: individuals have a diminished interest in regular somatic cells (skin, muscle, etc.) while courts have recognized that people retain a heightened property interest in reproductive cells such as sperm, eggs, and embryos. The articulated reason for the differential property interests in these two cell types is that embryos and gametes...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...